Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by J.W. Cole Advisors Inc.

J.W. Cole Advisors Inc. cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 719 shares of the biopharmaceutical company’s stock after selling 36 shares during the period. J.W. Cole Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $756,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brown Lisle Cummings Inc. lifted its position in Regeneron Pharmaceuticals by 18.2% during the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 10 shares during the period. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 10 shares during the period. Team Hewins LLC grew its position in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Team Hewins LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $434,000 after buying an additional 11 shares during the last quarter. Angeles Wealth Management LLC increased its stake in Regeneron Pharmaceuticals by 3.5% in the 1st quarter. Angeles Wealth Management LLC now owns 325 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 11 shares during the period. Finally, TrinityPoint Wealth LLC raised its position in Regeneron Pharmaceuticals by 4.8% during the 4th quarter. TrinityPoint Wealth LLC now owns 262 shares of the biopharmaceutical company’s stock worth $230,000 after buying an additional 12 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at $1,467,684. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Bonnie L. Bassler sold 756 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at $1,467,684. The disclosure for this sale can be found here. In the last three months, insiders sold 10,026 shares of company stock worth $11,498,705. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.0 %

Regeneron Pharmaceuticals stock opened at $1,153.08 on Tuesday. The stock has a market cap of $127.05 billion, a PE ratio of 34.06, a P/E/G ratio of 3.97 and a beta of 0.12. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The stock has a 50-day moving average price of $1,126.24 and a 200 day moving average price of $1,027.77. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the previous year, the business posted $8.79 earnings per share. The company’s revenue was up 12.3% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $1,250.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, September 5th. StockNews.com raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 10th. Morgan Stanley decreased their price target on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Cantor Fitzgerald reissued a “neutral” rating and issued a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, Piper Sandler boosted their target price on shares of Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, sixteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,109.70.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.